Syndicate content


What happens when business training and capital programs get caught in the web of intrahousehold dynamics?

Markus Goldstein's picture
Two weeks ago, I blogged about a new paper by Arielle Bernhardt and coauthors which looked at the idea that when women receive a cash infusion from a program, they may give it to their husbands to invest in their business.

Money for her or for him? Unpacking the impact of capital infusions for female enterprises

Markus Goldstein's picture
In a 2009 paper, David McKenzie and coauthors Chris Woodruff and Suresh de Mel find that giving cash grants to male entrepreneurs in Sri Lanka has a positive and significant return, while giving the same to women did not.   David followed this up with work with coauthors in Ghana that compared in-kind and cash grants for women and men.  Again, better returns for men (with in-kind working for some

Measured Profit is not Welfare or is it? Intriguing evidence from when microfinance clients gave up microfinance

David McKenzie's picture
I finally got around to reading an intriguing paper by Banerjee, Duflo and Hornbeck that has been on my reading list for a while. This paper is a nice example of making lemonade out of lemons – they had intended to evaluate a health insurance product that a microfinance organization in India made mandatory for its clients in selected villages.

The Mongolian Microfinance Experiment

David McKenzie's picture

I’ve been meaning to read for the last month this new paper by Orazio Attanasio and co-authors, which is the latest in the still small number of studies to carry out a randomized experiment to measure the impact of microfinance. David Roodman was quick to give his thoughts on it in this post, but I thought I’d also summarize it briefly for you and offer my thoughts.

Fighting Malaria with Microfinance?

David McKenzie's picture

Diseases like malaria, diarrhea and intestinal worms plague hundreds of millions of people in the developing world. A major puzzle for development researchers and practitioners is why the poor do not purchase available prevention technologies that could reduce the burden of these diseases. While much of the recent literature has focused on price elasticities of demand and behavioral explanations, another potential explanation is that liquidity constraints prevent the poor from undertaking profitable health investments.